These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25444750)

  • 1. PCSK9 and its modulation.
    Cui CJ; Li S; Li JJ
    Clin Chim Acta; 2015 Feb; 440():79-86. PubMed ID: 25444750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
    Guijarro C; Ruilope LM
    Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin kexin9 (PCSK9): a novel target for cholesterol regulation.
    Basak A; Palmer-Smith H; Mishra P
    Protein Pept Lett; 2012 Jun; 19(6):575-85. PubMed ID: 22519528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM; Dorsch MP; Bleske BE
    Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
    Marais AD; Kim JB; Wasserman SM; Lambert G
    Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
    Shimada YJ; Cannon CP
    Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding PCSK9 and anti-PCSK9 therapies.
    McKenney JM
    J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PCSK9 decade.
    Lambert G; Sjouke B; Choque B; Kastelein JJ; Hovingh GK
    J Lipid Res; 2012 Dec; 53(12):2515-24. PubMed ID: 22811413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
    Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 and lipid lowering drugs.
    Guo YL; Zhang W; Li JJ
    Clin Chim Acta; 2014 Nov; 437():66-71. PubMed ID: 25036764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PCSK9 for hypercholesterolemia.
    Norata GD; Tibolla G; Catapano AL
    Annu Rev Pharmacol Toxicol; 2014; 54():273-93. PubMed ID: 24160703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.